Prostatic Artery Embolization Using 100–300-μm Trisacryl Gelatin Microspheres to Treat Lower Urinary Tract Symptoms Attributable to Benign Prostatic Hyperplasia: A Single-Center Outcomes Analysis with Medium-Term Follow-up

PurposeTo report medium-term outcomes of prostatic artery embolization (PAE) using 100–300-μm trisacryl gelatin microspheres to treat lower urinary tract symptoms (LUTS) from benign prostatic hyperplasia (BPH) and to evaluate how cone-beam computed tomography-measured prostate gland volume (PGV), median lobe enlargement (MLE), age, and Charlson Comorbidity Index (CCI) affect these results.Materials and MethodsSeventy-four consecutive patients who underwent PAE from April 2014 through August 2018 were retrospectively reviewed. Patients had International Prostate Symptom Score (IPSS) >12, Quality of Life (QoL) score >2, prostate gland volume (PGV) >40 mL, age older than 45 years, and medical therapy failure. Twelve patients were excluded for bladder pathology or prostate cancer. Patients (n = 62, age = 71.8 ± 9.3 years, CCI = 3.5 ± 1.7, PGV = 174 ± 110 mL) had pre-procedure IPSS = 22.4 ± 5.6, QoL score = 4.4 ± 0.9, and post-void residual (PVR) = 172 ± 144 mL. Post-procedure values were compared to baseline at 1, 3, 6, 12, and 24 months. Associations between outcomes and PGV, MLE, age, and CCI were evaluated. Adverse event recording used Clavien-Dindo classification.ResultsOne month after PAE (n = 37), IPSS improved to 7.6 ± 5.2 (P < .0001) and QoL score improved to 1.7 ± 1.4 (P < .0001). At 3 months (n = 32), improvements continued, with IPSS = 6.4 ± 5.1 (P < .0001), QoL score = 1.2 ± 1.2 (P < .0001), PVR = 53 ± 41 mL (P < .001), and PGV = 73 ± 38 mL (P < .0001). Results were sustained at 6 months (n = 35): IPSS = 6.4 ± 4.1 (P < .0001), QoL score = 1.2 ± 1.2 (P < .0001), PVR = 68 ± 80 mL (P < .0001), PGV = 60 ± 19 mL (P < .001). At 12 months, patients (n = 26) had IPSS = 7.3 ± 5.5 (P < .0001), QoL score = 1.2 ± 0.8 (P <.0001), PVR = 89 ± 117 mL (P < .0001), PGV = 60 ± 48 mL (P < .01). At 24 months, patients (n = 8) had IPSS = 8.0 ± 5.4 (P < .0001), QoL score = 0.7 ± 0.5 (P < .0001), PVR = 91 ± 99mL (P = 0.17), and PGV = 30 ± 5mL (P = .11). Improvements were independent of PGV, MLE, age, and CCI. Two grade II urinary infections occurred.ConclusionsPAE with 100–300-μm microspheres produced sustained substantial improvements in LUTS, PGV, and PVR, which were independent of baseline PGV, MLE, age, or CCI.     

机器人辅助经尿道前列腺水消融术的临床应用进展

随着前列腺增生微创治疗的不断发展,机器人系统也被广泛引入其治疗当中,相比于机器人腹腔镜手术来说,本文着重介绍近年新出现的辅助水消融的自动化机器人系统。该系统经尿道的入路方式比传统腹腔镜机器人手术损伤更小,而且其处理系统相对简单,便于新手操作,从而降低了学习曲线,减少了手术时间和相关并发症。本文通过综述国外研究经验,为国内引入此技术提供参考借鉴。     

前列腺纤维化的研究进展

部分表现为下尿路症状(LUTS)的患者前列腺体积并不大,有证据支持前列腺纤维化是除BPH、平滑肌功能障碍之外,导致LUTS的原因之一。研究表明,前列腺纤维化的发生与各种原因导致的炎症、缺血缺氧、药物相关,具体机制涉及肌成纤维细胞的分化、聚集和活化。因此,抗炎、抗纤维化可能是治疗LUTS的潜在作用靶点。本文就前列腺纤维化的成因、诊断、与LUTS的关系及治疗进展作一综述。     

Factors Affecting Recurrent Deep Vein Thrombosis after Pharmacomechanical Thrombolysis and Left Iliac Vein Stent Placement in Patients with Iliac Vein Compression Syndrome

PurposeThis study evaluated the factors affecting contralateral and ipsilateral recurrent deep vein thrombosis (DVT) after iliac vein stent placement in patients with iliac vein compression syndrome (IVCS).Materials and MethodsData from 130 patients (95 female patients) who underwent catheter-directed thrombolysis and stent placement for IVCS with left lower leg thrombosis at a single institution were retrospectively analyzed. Mean patient age was 69.0 ± 14.0 years old. Median follow-up was 14 months (range, 3–164 months). Anticoagulation therapy was prescribed for 6 months, followed by lifelong antiplatelet therapy. Multivariate logistic regression analysis was performed to evaluate the factors affecting the development of contralateral and ipsilateral recurrent DVT.ResultsSeven patients (5.4%) developed contralateral DVT (median, 26 months; range, 2–61 months), and 11 patients (8.5%) developed ipsilateral DVT (median, 1 month; range, 0–53 months). Stent location (odds ratio [OR], 11.564; 95% confidence interval [CI], 1.159–115.417) and in-stent thrombosis during follow-up (OR, 15.142; 95% CI, 1.406–163.119) were predictors of recurrent contralateral DVT. Thrombophilia (OR, 47.560; 95% CI, 2.369–954.711), remaining inferior vena cava filter (OR, 30.552; 95% CI, 3.495–267.122), and in-stent thrombosis during follow-up (OR, 82.057; 95% CI, 2.915–2309.848) were predictors of ipsilateral DVT.ConclusionsContralateral DVT occurs late and is associated with extension of the iliac vein stent to the inferior vena cava and in-stent thrombosis. Ipsilateral DVT occurs relatively early and is associated with thrombophilia, remaining inferior vena cava filter, and in-stent thrombosis.     

Resultados preliminares de un trabajo multicéntrico a nivel nacional para el tratamiento de STUI secundario a hiperplasia benigna de próstata mediante el sistema con vapor de agua Rezūm®

Introduction and objectiveRezūm® system is a minimally invasive transurethral therapy that uses convective water vapor energy to ablate prostatic tissue. The objective is to report 1-year functional and security outcomes obtained by using this technique in real clinical practice.Material and methodsProspective study conducted in 5 Spanish hospitals for the treatment of LUTS secondary to BPH using the Rezūm® system. Patients with prostatic medium lobe (ML) and urethral catheter carriers were also included. Pre- and post-operative data were collected using IPSS, IIEF-5 and QoL questionnaires, flowmetry and post-void residual volume. Complications and retreatment rate at one-year follow-up were also reported.Results137 patients, including 64 with ML and 10 patients with urinary retention were treated. Median prostate volume was 50 cm³ (15-131). At 3 months follow-up, significant improvement was observed in IPSS (?6,37 points), Qmax (+4,95 mL/s) and QoL (?1,29); and was maintained until 12 months: ?10,78 points, +4,62 mL/s and ?2,73 respectively (p < 0.001). No significant changes were observed in the sexual sphere. All complications were mild (≤ Clavien II). Retreatment rate at one year was 4%.ConclusionShort-term results of this technique are promising, showing improvement in terms of functional outcomes, with no impact on the sexual sphere or complications. Longer term follow-up should include treatment durability and comparison to standard BPH treatments.     

Treatment of hemimandibular hyperplasia by computer-aided design and computer-aided manufacturing cutting and drilling guides accompanied with pre-bent titanium plates

PurposeThe treatment of hemimandibular hyperplasia (HH) is difficult by performing condylectomy and orthognathic surgery in one stage. This study investigated the clinical feasibility of treating HH with computer-aided design and computer-aided manufacturing (CAD/CAM) cutting and drilling guides and the pre-bent titanium plates to improve the accuracy of operation to avoid condyle reconstruction.Methods12 patients diagnosed with HH were included in this study from 2014 to 2018. Conservative condylectomy and bimaxillary orthognathic surgery were performed in all patients. The CAD/CAM cutting and drilling guides and the pre-bent titanium plates were used to guide surgeries. Follow-up and radiographic examinations were performed. The difference between virtually simulated and postoperative models was measured.ResultsAll patients got satisfactory and stable results, without complications or obvious relapse during follow-up. Occlusion relationship, temporomandibular joint function and facial symmetry were improved obviously after surgery. Comparison between simulated plans and actual postoperative outcomes showed that the surgical plans were transferred accurately.ConclusionsCAD/CAM cutting and drilling guides and the pre-bent titanium plates described in this paper can help transferring the results from computer simulation to the operating room accurately. Conservative condylectomy can be operated exactly matching bimaxillary orthognathic surgery for treating HH, avoiding condyle reconstruction.